The novel FOXM1 inhibitor STL001, developed by the first-generation modification in its parental compound STL427944, is more efficient in reducing the cellular FOXM1 activity in a variety of solid cancers and AML and potentially has the same high selectivity towards FOXM1. The gene discussed is FOXM1; the disease is acute myeloid leukemia.